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Abbreviations list 25 
Community-acquired pneumonia (CAP) 26 
Human Immunodeficiency Virus (HIV) 27 
Antiretroviral therapy (ART) 28 
White blood cell (WBC) count 29 
C-reactive protein (C-RP) 30 
Acute respiratory distress syndrome (ARDS) 31 
Tracheobronchial aspirates (TBAS) 32 
Bronchoalveolar lavage (BAL) 33 
Interquartile range (IQR) 34 
Standard deviation (SD) 35 
Mean (SD) 36 
Confidence interval (CI) 37 
Receiver operating characteristic (ROC)  38 
Minimal inhibitory concentration (MIC) 39 
Hepatitis C virus (HCV) 40 
Lactate deshydrogensase (LDH) 41 
Pneumonia Severe Index (PSI) 42 
Consciousness, Urea, Respiratory rate, Blood pressure, 65 years old (CURB-65) 43 
Chronic obstructive pulmonary disease (COPD) 44 
Intensive Care Unit (ICU) 45 
Length of stay (LOS) 46 
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ABSTRACT  53 
Background: The study aimed to investigate whether the clinical presentations and 54 
outcomes (length-of-stay (LOS), intensive care unit (ICU) admission and 30-day 55 
mortality) of pneumococcal pneumonia in virologically suppressed HIV-infected 56 
patients on ART with a CD4+ T cell count >350 cells/mm
3
 are comparable to those seen 57 
in non-HIV-infected patients, using a case-control design.  58 
Methods: A case-control study was carried out in Hospital Clinic, Barcelona, Spain 59 
(2001-2016). Controls were matched by age (±10 years), gender, co-morbidities and 60 
pneumonia diagnosis in the same calendar period. Clinical presentation and outcomes 61 
of pneumococcal pneumonia in HIV-infected patients and non-HIV-infected patients 62 
were compared. 63 
Results: Pneumococcal pneumonia was studied in 50 cases (HIV-infection) and 100 64 
controls (non-HIV-infection). Compared with the control patients, case patients had 65 
higher rates of influenza (14% vs. 2%, p=0·007) and pneumococcal vaccination (10% vs. 66 
1%, p=0·016). The group of cases also presented a higher rate of co-infection with HBV 67 
(6% vs. 0%, p=0·036). Both groups presented similar ICU admission (18% vs. 27%, 68 
p=0·22), need for mechanical ventilation (12% vs. 8%; p=0·43), length of stay (7 days 69 
vs. 7 days, p<0·76) and 0% of 30-day mortality. No evidence was found of a more 70 
severe presentation or a worse clinical outcome in cases than in controls. 71 
Conclusions: Pneumococcal pneumonia episodes requiring hospitalization in 72 
virologically suppressed HIV-infected patients with >350 CD4+ T cell count/mm
3
 were 73 
neither more severe nor had worse prognosis compared with uninfected patients. 74 
These results support the fact that such patients do not need treatment, admission or 75 
care sites different to the general population. 76 
 77 
 78 
 79 
 80 
 81 
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 84 
 85 
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Introduction 88 
Community-acquired pneumonia (CAP) is still an important complication in HIV- 89 
infected patients, even in the era of combined antiretroviral therapy (ART)[1]. HIV-90 
infected patients are generally known to be more susceptible to pneumococcal 91 
infections with a higher rate of bacteremia than non-HIV-infected patients[2]. Several 92 
studies have examined microbial etiology and prognostic factors of CAP in HIV-infected 93 
patients[3-6]. Despite the high rate of bacterial pneumonia in HIV-infected patients, 94 
mortality rates are not higher than in non-HIV-infected patients. 95 
The data on clinical presentation and outcomes of pneumococcal CAP in HIV-infected 96 
patients are limited and conflicting, because these variables in HIV-infected patients 97 
are difficult to compare with those of non-HIV-infected patients, as bacterial 98 
pneumonia in non-HIV-infected patients often occurs in older subjects than in the HIV 99 
population [7]. It is known that the incidence of bacterial pneumonia is related to 100 
immunological status in HIV-infected patients; despite the introduction of ART, 101 
however, the risk of invasive pneumococcal disease remains 35 times greater in HIV-102 
infected patients than in similarly aged non-HIV-infected adults[8]. Nevertheless, there 103 
is no data on whether clinical presentation and outcomes of pneumococcal CAP in HIV-104 
infected patients with effective ART are similar to those of non-HIV-infected patients. 105 
The hypothesis was that both clinical presentation and outcomes are similar. The aim 106 
of this study, therefore, was to investigate whether the clinical presentations and 107 
outcomes (LOS, ICU admission and 30-day mortality) of pneumococcal pneumonia in 108 
virologically suppressed HIV-infected patients on ART with a CD4+ T cell count 109 
>350 cells/mm
3
 are comparable to those seen in non-HIV-infected patients, using a 110 
case-control design.  111 
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Patients and Methods 112 
Study Design and Patients 113 
A case-control study was carried out in Hospital Clinic, Barcelona, Spain. All 114 
consecutive cases of adult patients with CAP diagnosed between January 2001 and 115 
January 2016 were included. CAP was defined as the presence of a new infiltrate on 116 
chest x-ray, together with clinical signs and symptoms suggestive of lower respiratory 117 
tract infection. Mycobacterial and fungal infections (other than Pneumocystis jiroveci) 118 
were also recorded but not included in the analysis. The diagnosis of pneumococcal 119 
CAP was performed according to the following criteria. Definite diagnosis: positive 120 
blood culture or positive pleural fluid culture or positive urinary antigen test for 121 
pneumococcus; and presumptive diagnosis: positive culture of respiratory samples 122 
(sputum, bronchoalveolar aspirate and bronchoalveolar lavage) in patients with 123 
pulmonary infiltrates. 124 
Case Patients, Control Subjects and Matched Criteria 125 
Case patients were identified from our database of CAP patients. Case patients were 126 
defined as HIV-infected adults (age, ≥18 years and ≤50 years) with a diagnosis of 127 
pneumococcal pneumonia between 2001 and 2016, with a CD4 lymphocyte count of 128 
≥350 cells/mm
3
 and undetectable levels of HIV-RNA (copies/mL) on ART. 129 
Two control cases of pneumococcal pneumonia patients without HIV-infection were 130 
selected for each case patient and matched for the following variables: age (age of the 131 
case patients at the time of pneumococcal CAP ±10 years), sex, co-morbidities (chronic 132 
respiratory disease, diabetes mellitus, neurological disease, chronic cardiovascular 133 
disease, chronic liver disease, chronic renal disease) and CAP diagnosis in the same 134 
calendar period. 135 
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This study was approved by the local Institutional Review Board (Register #2009/5451). 136 
Patients remained anonymous and informed consent was waived due to the 137 
observational nature of the study. 138 
Study Variables 139 
After case patients and control subjects were identified, the following data were 140 
collected at the time of hospital admission: age, gender, HIV infection, AIDS-defining 141 
criteria, CD4+ cell count, plasma HIV viral load within the previous three months of 142 
admission, previous or current intravenous drug use, current smoking habits (>10 143 
pack-years), alcohol habits (ingestion of an estimated amount of >80 g alcohol per day 144 
for at least one year before presentation), co-morbidities (chronic respiratory disease, 145 
diabetes mellitus, neurological disease, chronic cardiovascular disease, chronic liver 146 
disease, chronic renal disease), antimicrobial treatment prior to hospital admission, 147 
ART, duration of symptoms before the diagnosis of pneumonia, physical examination 148 
clinical signs and symptoms (fever, cough, pleuritic pain, dyspnea, mental confusion, 149 
and aspiration, blood pressure, body temperature, respiratory rate, and heart rate), 150 
chest X-ray pattern (number of lobes affected, pleural effusion, and atelectasis), blood 151 
analysis (hemoglobin level, white blood cell (WBC) count, platelet count, serum 152 
creatinine levels, C-reactive protein (C-RP) levels, and other biochemical parameters), 153 
pulmonary complications (empyema, acute respiratory distress syndrome (ARDS) 154 
criteria, pleural effusion, surgical pleural draining), clinical events (cardiac arrhythmia, 155 
septic shock, acute renal failure) and antimicrobial treatment at admission. Pneumonia 156 
severity index (PSI) and CURB-65[9] scores were determined in all patients[10]. All 157 
surviving patients were visited or contacted by telephone within 30 days after 158 
discharge. 159 
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Microbiological Evaluation 160 
Microbiological investigation was performed on sputum, urine, two blood samples and 161 
nasopharyngeal swabs (see Supplementary Material). Pleural puncture, 162 
tracheobronchial aspirates (TBAS) and bronchoalveolar lavage (BAL) fluid, where 163 
available, were collected for Gram, Ziehl-Nielsen, May-Grünwald Giemsa and Gomori 164 
methenamine silver stains and for cultures for bacterial, fungal and mycobacterial 165 
pathogens. 166 
Sputum and blood samples were obtained for bacterial culture before the start of 167 
antibiotic therapy in the emergency department. Nasopharyngeal swabs for 168 
respiratory virus detection and urine samples for Streptococcus pneumoniae and 169 
Legionella pneumophila antigen detection were obtained within 24 hours of admission 170 
to hospital. Blood samples for serology of atypical pathogens and respiratory virus 171 
were performed at admission and at 4-6 weeks thereafter (see Supplementary 172 
Material). 173 
HIV-1 viral load was determined by Versant HIV-1 RNA 1·0 kPCR Siemens Diagnostics 174 
(Lower Limit of Quantification: 37 copies/mL; Upper Limit of Quantification: 175 
11,000,000 copies/mL) (Lower limit of quantification in the period 2007-09 176 
<50 copies/mL and in the period 2010-12 lower limit <37 copies/mL). 177 
Statistical Analysis 178 
A total sample size of 150 patients (50 patients in the case group and 100 patients in 179 
the control group, according to 1:2 allocation ratio) was estimated to provide at least a 180 
80% power and a two-sided alpha value of 0.05 to detect as statistically significant a 181 
difference of 25% in the percentage of patients admitted to ICU between groups (39% 182 
cases vs. 14% controls[11].Data are shown as number of patients (%) for categorical 183 
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variables and either median (interquartile range [IQR]) for continuous variables with 184 
non-normal distribution or mean (standard deviation [SD]) for those with normal 185 
distribution. Categorical variables were compared using the X
2
 test or the Fisher exact 186 
test. Continuous variables were compared using the t test or the nonparametric Mann-187 
Whitney test. Unconditional logistic regression analyses[12] were used to examine the 188 
associations between outcomes (ICU admission and prolonged length of hospital stay [ 189 
LOS >7 days; cut-off value the median value of LOS]) and risk factors (see the full list of 190 
variables in the Supplemental Material). First, each risk factor was tested individually, 191 
second, all risk factors which showed an association in the univariate model (p<0·10) 192 
were added into the multivariate model, and finally, a backward stepwise selection 193 
(pin<0·05, pout<0·10) was used to determine factors associated with ICU admission and 194 
prolonged LOS, with adjustment for one predefined covariate (i.e., the case-control). 195 
The odds ratio (OR) and 95% confidence interval (CI) were calculated. The Hosmer-196 
Lemeshow goodness-of-fit test was performed to assess the overall fit of the 197 
models[13]. Internal validation of the prediction models was conducted using ordinary 198 
nonparametric bootstrapping with 1,000 bootstrap samples and bias-corrected, 199 
accelerated 95% CIs[14]. Receiver operating characteristic (ROC) curves were 200 
constructed for the ability to predict ICU admission and prolonged LOS, using variables 201 
derived from the multivariate logistic regression models. Simple imputations of 202 
random effects were used, where necessary, for variables with missing values. The 203 
level of significance was set at 0·05 (2-tailed). All analyses were performed using IBM 204 
SPSS Statistics version 22·0 (Armonk, New York, USA). 205 
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Results 206 
General Patient Characteristics 207 
During the study period (January 2001 to January 2016), a total of 2,300 consecutive 208 
patients with CAP were admitted to our hospital. Of them, 525 (23%) were HIV-209 
infected patients. Matching was successful in 50 cases and 100 control subjects with 210 
CAP caused by Streptococcus pneumoniae. 211 
Cases Characteristics 212 
Of the 50 cases included, 35 (70%) were males, with a mean (SD) age of 46·5 (12·2) 213 
years. All cases were on ART, with the three most frequent ART regimens being: two 214 
nucleoside analogue reverse transcriptase inhibitors (NRTI) + one integrase strand 215 
transfer inhibitor (INSTI) (18 cases [38%]), 2 NRTI + 1 protease inhibitor (PI) (16 cases 216 
[33%]), and 2 NRTI + 1 non-nucleoside reverse transcriptase inhibitors (NNRTI) (13 217 
cases [27%]). The median CD4+ cell count was 517·5 (403; 700) /mm
3
 and the 218 
proportion of patients with undetectable viral load was 100%. Nadir CD4+ cell count 219 
<200 cells/μl was 19 (39%). AIDS-defining illness was present in 23 (47%) of cases. The 220 
majority of patients (76%) were classified as low risk class (PSI risk class I-III). 221 
Seventeen patients (34%) presented co-infection with HCV, HBV or both viruses. The 222 
most frequent complications were multilobar pneumonia (16 patients [32%]) and 223 
bacteremia (24 patients [51%]). Nine patients (18%) were admitted to the ICU and six 224 
of these (12%) required mechanical ventilation. The median (IQR) LOS was 7·0 (5·0; 225 
11·0) days. The overall 30-day mortality was 0%. 226 
Comparison of Characteristics of Pneumonia Cases and Controls 227 
Baseline characteristics comparing cases and controls appear in Table 1. Cases and 228 
controls did not differ significantly in terms of baseline characteristics. Compared with 229 
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the control cases, the case patients had higher rates of influenza and pneumococcal 230 
vaccination. The group of cases also presented a higher rate of co-infection with HBV. 231 
Also, the co-infection with HCV seemed to be higher in the case group than the control 232 
group (Table 1) but no statistically significant difference was found (p=0·059). The 233 
control group more frequently presented pleural pain as a symptom and pleural 234 
effusion as a complication when compared with case patients. 235 
Microbiological Findings, Antimicrobial Resistance and Pneumococcal Serotypes 236 
With regard to microbiological diagnosis, 46 patients (92%) in the case group had a 237 
definitive diagnosis of pneumococcal pneumonia and 4 patients (8%) were diagnosed 238 
with presumptive diagnosis. In the control group, 90 patients (90%) had a definitive 239 
diagnosis of pneumococcal pneumonia and 10 patients (10%) were diagnosed with 240 
presumptive diagnosis. The percentages of patients with positive microbiological test 241 
results are shown in Table 2. 242 
We did not observe any association between pneumococcal vaccination and the 243 
incidence of bacteremia in either HIV (23 [55%] vs. 1 [20%]; p=0.19) or non-HIV (37 244 
[43%] vs. 1 [100%]; p=0.43) patients.  245 
Minimal inhibitory concentration (MIC) testing was performed in 82 out of 121 of the 246 
S. pneumoniae isolates (68%). A total of 11 pneumococcal isolates showed some 247 
degree of penicillin non-sensitivity. In addition, 13 pneumococcal isolates were non-248 
susceptible to erythromycin and there was a significant difference in regard to the 249 
erythromycin resistance between groups (9 cases [31%] vs. 4 controls [8%]; p=0·005). 250 
Thirty-four out of 69 invasive isolates (49%) were available for serotyping. The most 251 
frequent serotypes in the whole population were 1 (n=10, 29%), 7F (n=7, 21%), 9N 252 
(n=3, 9%), 3 (n=3, 9%), 19A (n=2, 6%), 14 (n=2, 6%), 13 (n=2, 6%), and 4 (n=4, 6%), as 253 
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summarized in e-Table 1. Serotypes covered by the PCV13 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 254 
18C, 19A, 19F, and 23F) vaccine represented 79% of all serotypes, and 21% were not 255 
included in this vaccine. No significant differences were observed in the distribution of 256 
serotypes covered by the PCV13 between cases and controls (7 cases [70%] vs. 20 257 
controls [83%]; p=0·38). In 20 patients (83%) from the control group, however, 258 
serotypes (1, 19A, 3, 14, and 7F) that are described in the literature as being associated 259 
with complicated pneumococcal pneumonia were found[15]. Significant differences 260 
were observed in the distribution of this group of serotypes between cases and 261 
controls (4 cases [40%] vs. 20 controls [83%]; p=0·034) (e-Table 2). A further analysis 262 
was performed comparing this group of serotypes (1, 19A, 3, 14 and 7F) in patients 263 
with and without empyema; however, the numbers are smaller and differences were 264 
not statistically significant (0 empyema cases in the case group vs. 7 cases in the 265 
control group; p=0·15) (data not shown). 266 
Empirical Antibiotic Therapy  267 
The most frequent regimens were ß-lactam plus macrolide (28 cases [56%] vs. 45 268 
controls [45%]; p=0·23), ß-lactam plus fluoroquinolones (10 cases [20%] vs. 19 controls 269 
[19%]; p>0·99), fluoroquinolone monotherapy (5 cases [10%] vs. 21 controls [21%]; 270 
p=0·093), and ß-lactam monotherapy (4 cases [8%] vs. 7 controls [7%]; p>0·99). All 271 
regimens were administered similarly in case and control patients. 272 
Outcomes  273 
Rate of ICU admission was similar in case and control groups (18% vs. 27%; p=0·22). 274 
Furthermore, the need for mechanical ventilation was similar for case and controls 275 
(12% vs. 8%; p=0·43). The LOS was also similar between case and controls (7 [5; 11] 276 
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days vs. 7 [4; 161] days; p=0·76). None of the patients included in either group died 277 
(Table 3). 278 
Prognostic Factors 279 
We performed univariate and multivariate analyses for ICU admission and prolonged 280 
LOS. In the first multivariate logistic regression analysis, the following factors were 281 
independently associated with ICU admission: PSI risk class IV-V, levels of LDH 282 
<498 U/L and the presence of multilobar involvement (Table 4). The area under the 283 
ROC curve was 0·81 (95% CI 0·72-0·89) for the model predictive of ICU admission.  284 
In the second multivariate logistic regression analysis for prolonged LOS (>7 days), the 285 
following factors were independently associated: chronic lung disease, LDH ≥498 U/L, 286 
multilobar involvement, pleural effusion and invasive mechanical ventilation (Table 5). 287 
The area under the ROC curve was 0·84 (95% CI 0·78 to 0·91) for the model predictive 288 
of prolonged LOS (>7 days). HIV-infection was not associated with ICU admission or 289 
increased LOS in the multivariate analysis, even after adjustments for case patient and 290 
potential confounding factors.  291 
Internal validation of the two logistic regression models was conducted using 292 
bootstrapping with 1,000 samples. All the variables included in the models for ICU 293 
admission and prolonged LOS demonstrated robust results, with small 95% CIs around 294 
the original coefficients, except for invasive mechanical ventilation in the model for 295 
prolonged LOS, which appeared to be less reliable with wider 95% CIs around the 296 
original coefficients (e-Table 3 and e-Table 4). 297 
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Discussion 298 
To the best of our knowledge, this is the first case-control study addressing the issue of 299 
hospitalized pneumococcal CAP in virologically suppressed HIV-Infected patients with 300 
>350 CD4+ T cells/mm
3
. The most important finding of this study is that hospitalized 301 
HIV-infected patients with pneumococcal CAP did not have a more severe presentation 302 
or worse clinical outcome than uninfected patients. Also, in multivariate analysis we 303 
found no evidence that HIV-infection was a risk factor for ICU admission or longer LOS 304 
(>7 days).  305 
There is conflicting information regarding clinical presentation and outcomes of 306 
hospitalized HIV-infected patients with CAP [4;16-18]. Some studies have shown that 307 
mortality or LOS is unaffected by HIV infection whereas others have shown the 308 
opposite. Feldman et al[19] reported significant differences in the clinical presentation 309 
and outcome of bacteremic pneumococcal pneumonia when comparing HIV and non-310 
HIV patients. In this study, HIV-infected patients had more clinical symptoms, 311 
especially among those with lower CD4 cell counts. In our study, case patients 312 
presented with rates of bacteremia of nearly 50%. In a larger series from our group, on 313 
HIV and CAP (331 patients), published in 2014, 100 patients had pneumococcal CAP 314 
and 50% of them also had bacteremia[6]. Other series have reported rates of 315 
bacteremia ranging from 23% to 75% [16;20;21]. In the same way, Mayaud et al[7] 316 
reported differences in presentation of CAP between HIV-infected and uninfected 317 
patients, high rates of bacteremia and pleural effusion are presented in HIV-infected 318 
patients. Nevertheless, the study by Bordon et al[18] showed that clinical outcomes of 319 
HIV-infected patients with CAP are not predicted by CD4+ T cell count or HIV-RNA 320 
levels; they comment that management of CAP in patients with HIV infection should 321 
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not be based on CD4+ T cell count or HIV-RNA levels of the HIV infection. Also, a 322 
secondary analysis of this data showed that the presence of HIV infection did not 323 
influence the clinical outcomes of CAP[22]. According to this study, there was no 324 
evidence that HIV-infected patients with pneumococcal pneumonia have a more 325 
severe presentation or worse clinical outcomes than HIV-uninfected patients. Our 326 
results are also in line with these findings. We found that clinical presentations and 327 
outcomes are similar between virologically suppressed HIV-infected patients and 328 
uninfected patients with pneumococcal pneumonia.  329 
The patients in this study were young, with mainly low severity scores. The mortality 330 
rate is not surprising and is low according to the PSI score, although this could be due 331 
to the specific population analyzed. Differences were found in the presence of chest 332 
pain and pleural effusion between case and controls. Controls presented higher 333 
frequencies of chest pain and pleural fluid with statistical differences compared with 334 
the case group. Also, we found that the serotypes (1, 19A, 3, 14 and 7F) described in 335 
the literature as associated with complicated pneumococcal pneumonia[15] were 336 
more frequently observed in the control group (40% vs. 83%; p=0·034). These results 337 
explain the higher rate of chest pain, pleural effusion and the higher percentages of 338 
empyema in the case group. Because the physician in charge of patients takes the 339 
thoracentesis decision directly, we do not have a clear explanation as to the low rate 340 
of thoracentesis in case patients. One possibility is the higher amount of radiographic 341 
pleural fluid observed in cases compared to controls being probably due to the 342 
concern of an alternative diagnosis in HIV-infected patients. 343 
There are currently no specific guidelines or recommendations for virologically 344 
suppressed HIV-infected patients on ART with >350 CD4 cells/mm
3
, and these results 345 
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support the approach whereby these patients do not need specific treatments, 346 
hospital admission or sites of care that are different to the general population. 347 
Despite a higher rate of vaccination in the case group, only 10% and 14% of HIV-348 
infected patients were vaccinated against pneumococcus and influenza, respectively. 349 
We did not find any association between pneumococcal vaccination and the rate of 350 
bacteremia in our study. This result highlights the importance of improving these 351 
vaccinations in the HIV-population (as recommended by all international guidelines), in 352 
particular because most of the pneumococcus serotypes in the case group were 353 
included among those present in 13V pneumococcal vaccine.  354 
Our study has a number of limitations. First, the defined sample size is too small to 355 
make a robust analysis of all related questions. The sample-size calculation was based 356 
on the percentage of patients admitted to ICU, where a total sample size of 150 357 
patients (50 patients in the case group and 100 patients in the control group, according 358 
to 1:2 allocation ratio) is large enough if the expected difference is 25%. However, 359 
when comparing several characteristics between the two groups of patients, i.e. 360 
outcomes, the current study was underpowered. Second, as the data were collected 361 
from a single academic teaching hospital in Spain, the results might not generalize to 362 
other patients admitted to other types of hospitals in other countries. Third, the study 363 
took place over a long period; the protocols and microbiologic procedures have not, 364 
however, substantially changed during those years. Finally, the low mortality ratio in 365 
our study limits the generalization of our results. However, there are no data in the 366 
literature showing that virologically suppressed HIV-infected patients on ART should be 367 
treated in the same way as non-HIV infected patients. 368 
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In conclusion, this study describes a subpopulation of hospitalized virologically 369 
suppressed HIV-infected patients on ART with >350 CD4 cells/mm
3
 and pneumococcal 370 
pneumonia in whom clinical presentation and outcomes did not differ from uninfected 371 
patients. The management of these HIV-infected patients should be the same as for 372 
HIV-uninfected individuals and should be included in the CAP management guidelines.  373 
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Table 1. Baseline Characteristics of the Whole Population 
Variables 
Case Patients 
(HIV-infection) 
(n = 50) 
Control Patients 
(non-HIV-infection) 
(n = 100) 
P value 
Age, mean (SD), years 46·5 (12·2) 47·5 (11·5) 0·64 
Male sex, n (%) 35 (70) 70 (70) >0·99 
Current smoker, n (%) 34 (68) 56 (56) 0·16 
Current alcohol abuse, n (%) 13 (26) 24 (24) 0·79 
Previous antibiotic, n (%) 3 (6) 10 (10) 0·55 
Influenza vaccine, n (%) 7 (14) 2 (2) 0·007 
Pneumococcal vaccine, n (%) 5 (10) 1 (1) 0·016 
Length of symptoms, median (IQR), days 3·0 (2·0; 5·0) 3·0 (2·0; 5·0) 0·91 
Comorbidity, n (%)
a
 13 (26) 26 (26) >0·99 
    Chronic respiratory disease 7 (14) 13 (13) >0·99 
    Diabetes mellitus 2 (4) 4 (4) >0·99 
    Chronic  renal disease 1 (2) 2 (2) >0·99 
    Chronic  liver disease 3 (6) 7 (7) >0·99 
Co-infection with HCV, n (%) 12 (24) 12 (12) 0·059 
Co-infection with HBV, n (%) 3 (6) 0 0·036 
Co-infection with HCV/HBV, n (%) 2 (4) 2 (2) 0·60 
Calendar year diagnosis, n (%)   >0·99 
    2001-2008 13 (26) 26 (26)  
    2009-2016 37 (74) 74 (74)  
Symptoms, n (%)    
    Fever 42 (84) 89 (89) 0·43 
    Cough 38 (76) 78 (78) 0·83 
    Purulent sputum 28 (56) 51 (51) 0·60 
    Pleuritic pain 23 (46) 69 (69) 0·008 
Laboratory findings, median (IQR)    
    Creatinine, mg/dL 1·0 (0·9; 1·4) 1·1 (0·9; 1·4) 0·52 
    C-reactive protein, mg/dL 25·1 (13·8; 29·4) 25·0 (17·5; 29·7) 0·78 
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Variables 
Case Patients 
(HIV-infection) 
(n = 50) 
Control Patients 
(non-HIV-infection) 
(n = 100) 
P value 
    White blood cell count, x10
9
 cell/L 11·9 (8·9; 16·6) 13·3 (9·2-19·6) 0·54 
    LDH, UI/L 387 (306; 500) 450 (350; 618) 0·16 
    Sat 02, % 92·7 (89·9; 95·2) 93·2 (89·3; 95·0) 0·98 
    PaO2/FIO2 276·2 (228·6; 342·9) 279·5 (242·9; 314·3) 0·91 
Pneumonia Severity Index risk class, n (%)
b
   0·57 
    I-III 38 (76) 80 (80)  
    IV-V 12 (24) 20 (20)  
CURB-65 score, n (%)
c
   0·61 
    0-2 45 (94) 91 (94)  
    3-5 3 (6) 6 (6)  
Multilobar involvement, n (%) 16 (32) 32 (32) >0·99 
Pleural effusion, n (%) 6 (12) 28 (28) 0·027 
Respiratory distress, n (%) 6 (6) 4 (8) 0·73 
Septic shock, n (%) 3 (6) 3 (3) 0·40 
Acute renal failure, n (%) 21 (21) 12 (24) 0·68 
Abbreviations: CURB-65 indicates consciousness, urea, respiratory rate, blood pressure, 65; HAART, 
highly active antiretroviral therapy; ICU, intensive care unit; IQR, interquartile range; LDH, lactate 
dehydrogenase; Sat O2, oxygen saturation; SD, standard deviation. 
a
 Could have more than 1 comorbid condition. 
b
 Stratified according to 30-day risk mortality for community-acquired pneumonia: risk classes I-III (≤90 
points) have low mortality and risk classes IV-V (>90 points) have the highest mortality. 
c
 Stratified according to 30-day risk mortality for community-acquired pneumonia: risk scores 0-2 have 
low mortality and risk scores 3-5 have the highest mortality. 
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Table 2. Microbial Diagnosis of Pneumococcal Pneumonia 
Microbiological Test Case Patients 
(HIV-infection) 
 
Control Patients 
(non-HIV-infection) 
 
P value 
Blood culture 24 / 47 (51) 38 / 88 (43) 0·38 
Pleural fluid 0 / 3 (0) 7 / 18 (39) 0·52 
Urine pneumococcal antigen 38 / 43 (88) 72 / 85 (85) 0·57 
Sputum 16 / 31 (52) 32 / 63 (51) 0·94 
Bronchoalveolar lavage 1 / 5 (20) 3 / 7 (43) 0·58 
Data are expressed as no. of patients with positive result / no. of patients tested (%). 
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Table 3. Clinical Outcomes 
Variables 
Case Patients 
(HIV-infection) 
 (n = 50) 
Control Patients 
(non-HIV-infection) 
 (n = 100) 
P value 
ICU admission, n (%) 9 (18) 27 (27) 0·22 
Mechanical ventilation, n (%) 6 (12) 8 (8) 0·43 
Length of hospital stay, median (IQR), days 7·0 (5·0; 11·0) 7·0 (4·0; 11·0) 0·76 
30-day mortality, n (%) 0 (0) 0 (0) - 
Abbreviations: IQR indicates interquartile range. 
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Table 4. Significant Univariate and Multivariate Logistic Regression Analyses for ICU 
Admission 
Abbreviations: CI indicates confidence interval; ICU, intensive care unit; LDH, lactate dehydrogenase; 
OR, odds ratio. 
a
 Hosmer-Lemeshow goodness-of-fit test, p=0·39. 
b
 Optimal cut-off value of cases and 
controls using ROC curves.  
 
Variable 
Univariate Multivariate
a
 
OR 95% CI P value OR 95% CI P value 
Case Patients (HIV-infection) 0·59 0·25 to 1·38 0·23 0·60 0·23 to 1·59 0·30 
C-reactive protein level 
≥14·75 mg/dL
b
 
6·63 1·50 to 29·24 0·012 - - - 
LDH <498 U/L
b
 2·10 1·01 to 4·38 0·047 2·68 1·11 to 6·48 0·028 
Pneumonia Severity Index 
risk class  IV-V 
4·90 2·11 to 11·39 <0·001 5·68 2·15 to 14·95 <0·001 
Multilobar involvement 4·51 2·05 to 9·95 <0·001 5·32 2·18 to 13·00 <0·001 
Pleural effusion 2·50 1·09 to 5·73 0·030 - - - 
Acute renal failure 4·56 1·98 to 10·52 <0·001 - - - 
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Table 5. Significant Univariate and Multivariate Logistic Regression Analyses for 
Prolonged LOS (>7 days) 
Abbreviations: CI indicates confidence interval; LDH, lactate dehydrogenase; LOS, length of hospital stay; 
OR, odds ratio. 
a
 Hosmer-Lemeshow goodness-of-fit test, p=0·94. 
b
 Optimal cut-off value of cases and 
controls using ROC curves 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable 
Univariate Multivariate
a
 
OR 95% CI P value OR 95% CI P value 
Case Patients (HIV-infection) 1·08 0·55 to 2·14 0·82 2·14 0·88 to 5·21 0·093 
Chronic lung disease 3·39 1·22 to 9·39 0·019 6·88 2·06 to 22·94 0·002 
LDH ≥498 U/L
b
 2·13 1·09 to 4·14 0·026 3·06 1·26 to 7·43 0·014 
Pneumonia Severity Index 
risk class IV-V 
2·13 0·96 to 4·72 0·062 - - - 
Multilobar involvement 4·40 2·11 to 9·19 <0·001 3·59 1·46 to 8·85 0·005 
Pleural effusion 9·21 3·52 to 24·12 <0·001 17·76 5·60 to 56·32 <0·001 
Acute renal failure 2·29 1·04 to 5·05 0·040 - - - 
Invasive mechanical 
ventilation 
11·12 1·35 to 91·31 0·025 12·81 1·41 to 116·57 0·024 
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e-Appendix 1.  
METHODS 
Statistical Analysis 
Receiver operating characteristic (ROC) curves were constructed to determine the best cut-points 
for C-reactive protein and lactate dehydrogenase (LDH) in relation to case-control patients. 
Youden’s index[1] was defined for all points along the ROC curve, and the maximum value of the 
index was used as a criterion for selecting the optimum cut-off point. To identify factors associated 
with outcomes (intensive care unit [ICU] admission and prolonged length of hospital stay [LOS; 
LOS >7 days; cut-off value the median value of LOS]) unconditional logistic regression models 
were used[2]. Variables were included in the multivariate model when univariate comparisons 
yielded a level of significance of p<0·10. The following variables were tested: age (<65 vs. ≥65 
years), gender, previous antibiotic, influenza vaccination, pneumococcal vaccination, inhaled 
corticosteroids, systemic corticosteroids, chronic pulmonary disease, chronic cardiovascular 
disease, diabetes mellitus, neurological disease, chronic renal disease, chronic liver disease, 
pleuritic pain, fever, altered mental status, dyspnea, C-reactive protein (<14·75 vs. ≥14·75 
mg/dL), white blood cell count (<10 vs. ≥10 x109 cells/L), LDH (<498 vs. ≥498 U/L), Sat O2 
(<92% vs. ≥92%), PaO2/FiO2 (<250 vs. ≥250), multilobar affectation, pleural effusion, septic 
shock, and acute renal disease. To identify the problem of colinearity, the r coefficient of two 
variables were calculated. Where two independent variables were highly correlated (r >|±0·30|), 
the variable with the largest variance was excluded from the multivariate analysis[3]. 
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e-Table 1. Serotype Distribution 
Pneumococcal 
Serotype 
Case Patients 
(HIV-infection) 
 (n = 10) 
Control Patients 
(non-HIV-infection) 
 (n = 24) 
P value 
1 0 (0) 10 (42) 0·017 
3 0 (0) 3 (13) 0·54 
4 2 (20) 0 (0) 0·080 
5 1 (10) 0 (0) 0·29 
7F 4 (40) 3 (13) 0·071 
9N 1 (10) 2 (8) >0·99 
13 1 (10) 1 (4) 0·51 
14 0 (0) 2 (8) >0·99 
19A 0 (0) 2 (8) >0·99 
22F 0 (0) 1 (4) >0·99 
29 1 (10) 0 (0) 0·29 
Abbreviations: HIV indicates human immunodeficiency virus. 
Data are expressed as no. of patients (%). 
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e-Table 2. Serotype Associated with Complicated Pneumococcal Pneumonia (1, 3, 7F, 14, 
and 19A) Versus Not Associated (4, 5, 9N, 13, 22 and 29) 
Pneumococcal Serotype Case Patients 
(HIV-infection) 
 (n = 10) 
Control Patients 
(non-HIV-
infection) 
 (n = 24) 
P value 
Serotype associated with complicated 
pneumococcal pneumonia: 
1, 3, 7F, 14, and 19A 
4 (40) 20 (83) 0·034 
Serotype not associated with complicated 
pneumococcal pneumonia: 
4, 5, 9N, 13, 22 and 29 
6 (60) 4 (17) 
Abbreviations: HIV indicates human immunodeficiency virus. 
Data are expressed as no. of patients (%). 
 
 
 
 
 
e-Table 3. Internal Validation of the Multivariate Logistic Regression Model for ICU 
Admission Using Nonparametric Bootstrap Technique 
Variable Original Bias SE 95% BCa CI 
Case Patients (HIV-infection) -0·509 -0·040 0·549 -1·758 to 0·407 
LDH <498 U/La 0·986 0·049 0·473 0·088 to 2·005 
Pneumonia Severity Index risk class IV-V 1·736 0·089 0·569 0·728 to 3·055 
Multilobar involvement 1·672 0·082 0·510 0·732 to 2·768 
Abbreviations: BCa indicates adjusted bootstrap; CI, confidence interval; HIV, human 
immunodeficiency virus; ICU, intensive care unit; LDH, lactate dehydrogenase; SE, standard error. 
a Optimal cut-off value of cases and controls using ROC curves. 
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e-Table 4. Internal Validation of the Multivariate Logistic Regression Model for Prolonged 
LOS Using Nonparametric Bootstrap Technique 
Variable Original Bias SE 95% BCa CI 
Case Patients (HIV-infection) 0·762 0·053 0·498 -0·188 to 1·804 
Chronic lung disease 1·929 0·155 0·691 0·840 to 3·558 
LDH ≥498 U/La 1·118 0·086 0·530 0·147 to 2·341 
Multilobar involvement 2·877 0·260 1·412 1·845 to 4·610 
Pleural effusion 1·278 0·071 0·494 0·403 to 2·361 
Invasive mechanical ventilation 2·550 6·644 9·466 0·380 to 22·329 
Abbreviations: BCa indicates adjusted bootstrap; CI, confidence interval; HIV, human 
immunodeficiency virus; LDH, lactate dehydrogenase; LOS, length of hospital stay; SE, standard 
error. 
a Optimal cut-off value of cases and controls using ROC curves. 
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